Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 410 in KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Jul 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 1, open-label trial of AMG 410 in solid tumor (6 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 3 years and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
AMG 410
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07094113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094113.